Parkinson's Disease (PD) A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease Phase 2 PD0053 Completed NCT046581862020-003265-19 Price D., Khan A., Angers R., Cardenas A., Key-Prato ...